title: Haber's syndrome may be a clinical entity different from Dowling-Degos disease.
authors.forename: A
authors.initials: A
authors.lastname: Nishizawa
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Takayama
authors.forename: D
authors.initials: D
authors.lastname: Sawamura
authors.forename: H
authors.initials: H
authors.lastname: Yokozeki
mesh_terms: D000368:Aged; D025063:Chromosome Disorders / Q000235:genetics / Q000473:pathology*; D058534:Class I Phosphatidylinositol 3-Kinases; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000235:genetics / Q000473:pathology; D053555:Keratin-5 / Q000235:genetics*; D017492:Keratosis, Seborrheic / Q000235:genetics / Q000473:pathology*; D010375:Pedigree; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics; D012871:Skin Diseases / Q000235:genetics / Q000473:pathology*; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: C503940:KRT5 protein, human; D053555:Keratin-5; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3